Persons using assistive technology might not be able to fully access information in this file. For assistance, please send e-mail to: mmwrq@cdc.gov. Type 508 Accommodation and the title of the report in the subject line of e-mail.
TABLE 2. Approved influenza vaccines for different age groups --- United States, 2009--10 season
Vaccine
Trade name
Manufacturer
Presentation
Mercury content (mcg Hg/0.5 mL dose)
Age group
No. of doses
Route
TIV*
Fluzone
Sanofi Pasteur
0.25mL prefilled syringe
0.5 mL prefilled syringe
0.5 mL vial
5.0 mL multidose vial
0
0
0
25
6--35 mos
≥36 mos
≥36 mos
≥6 mos
1 or 2†
1 or 2
1 or 2
1 or 2
Intramuscular§
Intramuscular
Intramuscular
Intramuscular
TIV
Fluvirin
Novartis Vaccine
5.0 mL multidose vial 0.5 mL prefilled syringe
25 <1.0
≥4 yrs
1 or 2
Intramuscular
TIV
Fluarix
GlaxoSmithKline
0.5 mL prefilled syringe
0
≥18 yrs
1
Intramuscular
TIV
FluLaval
GlaxoSmithKline
5.0 mL multidose vial
25
≥18 yrs
1
Intramuscular
TIV
Afluria
CSL Biotherapies
0.5 mL prefilled syringe 5.0 mL multidose vial
0
25
≥18 yrs
1
Intramuscular
LAIV¶
FluMist**
MedImmune
0.2 mL sprayer
0
2--49 yrs
1 or 2††
Intranasal
* Trivalent inactivated vaccine. A 0.5-mL dose contains 15 mcg each of A/Brisbane/59/2007 (H1N1)-like, A/Brisbane/10/2007 (H3N2)-like, and B/Brisbane/ 60/2008-like antigens.
† Two doses administered at least 1 month apart are recommended for children aged 6 months--8 years who are receiving TIV for the first time and those who only received 1 dose in their first year of vaccination should receive 2 doses in the following year.
§ For adults and older children, the recommended site of vaccination is the deltoid muscle. The preferred site for infants and young children is the anterolateral aspect of the thigh.
¶ Live attenuated influenza vaccine. A 0.2-mL dose contains 106.5--7.5 fluorescent focal units of live attenuated influenza virus reassortants of each of the three strains for the 2008--09 influenza season: A/Brisbane/59/2007(H1N1), A/Brisbane/10/2007(H3N2), and B/Brisbane/60/2008.
** FluMist is shipped refrigerated and stored in the refrigerator at 2°C--8°C (36°F to 46°F) after arrival in the immunization clinic. The dose is 0.2 mL divided equally between each nostril. FluMist should not be administered to persons with asthma. Health-care providers should consult the medical record, when available, to identify children aged 2--4 years with asthma or recurrent wheezing that might indicate asthma. In addition, to identify children who might be at greater risk for asthma and possibly at increased risk for wheezing after receiving FluMist, parents or caregivers of children aged 2--4 years should be asked: "In the past 12 months, has a health-care provider ever told you that your child had wheezing or asthma?" Children whose parents or caregivers answer "yes" to this question and children who have asthma or who had a wheezing episode noted in the medical record during the preceding 12 months should not receive FluMist.
†† Two doses administered at least 4 weeks apart are recommended for children aged 2--8 years who are receiving LAIV for the first time, and those who only received 1 dose in their first year of vaccination should receive 2 doses in the following year.
Use of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of
Health and Human Services.References to non-CDC sites on the Internet are
provided as a service to MMWR readers and do not constitute or imply
endorsement of these organizations or their programs by CDC or the U.S.
Department of Health and Human Services. CDC is not responsible for the content
of pages found at these sites. URL addresses listed in MMWR were current as of
the date of publication.
All MMWR HTML versions of articles are electronic conversions from typeset documents.
This conversion might result in character translation or format errors in the HTML version.
Users are referred to the electronic PDF version (http://www.cdc.gov/mmwr)
and/or the original MMWR paper copy for printable versions of official text, figures, and tables.
An original paper copy of this issue can be obtained from the Superintendent of Documents, U.S.
Government Printing Office (GPO), Washington, DC 20402-9371;
telephone: (202) 512-1800. Contact GPO for current prices.
**Questions or messages regarding errors in formatting should be addressed to
mmwrq@cdc.gov.
